☰

Jason D. Graci, Ph.D. - Publications

Affiliations: 
2007 Pennsylvania State University, State College, PA, United States 
Area:
Virology Biology, Biochemistry, Molecular Biology
Tree Info Similar researchers PubMed Report error

23 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Luban J, Sattler R, Mühlberger E, Graci JD, Cao L, Weetall M, Trotta C, Colacino JM, Bavari S, Strambio-De-Castillia C, Suder EL, Wang Y, Soloveva V, Cintron-Lue K, Naryshkin NA, et al. The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines. Virus Research. 198246. PMID 33249060 DOI: 10.1016/j.virusres.2020.198246  0.306
2020 Luban J, Sattler R, Mühlberger E, Graci JD, Cao L, Weetall M, Trotta C, Colacino JM, Bavari S, Strambio-De-Castillia C, Suder EL, Wang Y, Soloveva V, Cintron-Lue K, Naryshkin NA, et al. The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines. Biorxiv : the Preprint Server For Biology. PMID 32793904 DOI: 10.1101/2020.08.05.238394  0.306
2018 Cao L, Weetall M, Trotta C, Cintron K, Ma J, Kim MJ, Furia B, Romfo C, Graci JD, Li W, Du J, Sheedy J, Hedrick J, Risher N, Yeh S, et al. Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties. Molecular Cancer Therapeutics. PMID 30352802 DOI: 10.1158/1535-7163.Mct-18-0863  0.341
2016 Graci JD, Jung SP, Pichardo J, Lahser F, Tong X, Gu Z, Colacino JM. PTC725, an NS4B-targeting compound, inhibits an HCV genotype 3 replicon, as predicted by genome sequence analysis and determined experimentally. Antimicrobial Agents and Chemotherapy. PMID 27620477 DOI: 10.1128/Aac.01272-16  0.379
2015 Zhang N, Turpoff A, Zhang X, Huang S, Liu Y, Almstead N, Njoroge FG, Gu Z, Graci J, Jung SP, Pichardo J, Colacino J, Lahser F, Ingravallo P, Weetall M, et al. Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B. Bioorganic & Medicinal Chemistry Letters. PMID 26652483 DOI: 10.1016/J.Bmcl.2015.11.065  0.356
2015 Chen G, Ren H, Zhang N, Lennox W, Turpoff A, Paget S, Li C, Almstead N, Njoroge FG, Gu Z, Graci J, Jung SP, Colacino J, Lahser F, Zhao X, et al. 6-(Azaindol-2-yl)pyridine-3-sulfonamides as potent and selective inhibitors targeting hepatitis C virus NS4B. Bioorganic & Medicinal Chemistry Letters. 25: 781-6. PMID 25613678 DOI: 10.1016/J.Bmcl.2014.12.093  0.442
2014 Korboukh VK, Lee CA, Acevedo A, Vignuzzi M, Xiao Y, Arnold JJ, Hemperly S, Graci JD, August A, Andino R, Cameron CE. RNA virus population diversity, an optimum for maximal fitness and virulence. The Journal of Biological Chemistry. 289: 29531-44. PMID 25213864 DOI: 10.1074/Jbc.M114.592303  0.725
2014 Zhang N, Zhang X, Zhu J, Turpoff A, Chen G, Morrill C, Huang S, Lennox W, Kakarla R, Liu R, Li C, Ren H, Almstead N, Venkatraman S, Njoroge FG, ... ... Graci J, et al. Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B. Journal of Medicinal Chemistry. 57: 2121-35. PMID 24266880 DOI: 10.1021/Jm401621G  0.387
2013 Zhang X, Zhang N, Chen G, Turpoff A, Ren H, Takasugi J, Morrill C, Zhu J, Li C, Lennox W, Paget S, Liu Y, Almstead N, Njoroge FG, Gu Z, ... ... Graci J, et al. Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B. Bioorganic & Medicinal Chemistry Letters. 23: 3947-53. PMID 23683597 DOI: 10.1016/J.Bmcl.2013.04.049  0.393
2013 Gu Z, Graci JD, Lahser FC, Breslin JJ, Jung SP, Crona JH, McMonagle P, Xia E, Liu S, Karp G, Zhu J, Huang S, Nomeir A, Weetall M, Almstead NG, et al. Identification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C Virus NS4B protein. Antimicrobial Agents and Chemotherapy. 57: 3250-61. PMID 23629699 DOI: 10.1128/Aac.00527-13  0.403
2012 Graci JD, Gnädig NF, Galarraga JE, Castro C, Vignuzzi M, Cameron CE. Mutational robustness of an RNA virus influences sensitivity to lethal mutagenesis. Journal of Virology. 86: 2869-73. PMID 22190724 DOI: 10.1128/Jvi.05712-11  0.642
2011 Micheva-Viteva S, Kobayashi Y, Edelstein LC, Pacchia AL, Lee HL, Graci JD, Breslin J, Phelan BD, Miller LK, Colacino JM, Gu Z, Ron Y, Peltz SW, Dougherty JP. High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor. The Journal of Biological Chemistry. 286: 21083-91. PMID 21498519 DOI: 10.1074/Jbc.M110.195537  0.396
2008 Graci JD, Cameron CE. Therapeutically targeting RNA viruses via lethal mutagenesis. Future Virology. 3: 553-566. PMID 19727424 DOI: 10.2217/17460794.3.6.553  0.734
2008 Graci JD, Too K, Smidansky ED, Edathil JP, Barr EW, Harki DA, Galarraga JE, Bollinger JM, Peterson BR, Loakes D, Brown DM, Cameron CE. Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues. Antimicrobial Agents and Chemotherapy. 52: 971-9. PMID 18180344 DOI: 10.1128/Aac.01056-07  0.726
2008 Moriyama K, Suzuki T, Negishi K, Graci JD, Thompson CN, Cameron CE, Watanabe M. Effects of introduction of hydrophobic group on ribavirin base on mutation induction and anti-RNA viral activity. Journal of Medicinal Chemistry. 51: 159-66. PMID 18067241 DOI: 10.1021/Jm7009952  0.661
2007 Graci JD, Harki DA, Korneeva VS, Edathil JP, Too K, Franco D, Smidansky ED, Paul AV, Peterson BR, Brown DM, Loakes D, Cameron CE. Lethal mutagenesis of poliovirus mediated by a mutagenic pyrimidine analogue. Journal of Virology. 81: 11256-66. PMID 17686844 DOI: 10.1128/Jvi.01028-07  0.696
2007 Harki DA, Graci JD, Edathil JP, Castro C, Cameron CE, Peterson BR. Synthesis of a universal 5-nitroindole ribonucleotide and incorporation into RNA by a viral RNA-dependent RNA polymerase. Chembiochem : a European Journal of Chemical Biology. 8: 1359-62. PMID 17600792 DOI: 10.1002/Cbic.200700160  0.774
2006 Harki DA, Graci JD, Galarraga JE, Chain WJ, Cameron CE, Peterson BR. Synthesis and antiviral activity of 5-substituted cytidine analogues: identification of a potent inhibitor of viral RNA-dependent RNA polymerases. Journal of Medicinal Chemistry. 49: 6166-9. PMID 17034123 DOI: 10.1021/Jm060872X  0.741
2006 Graci JD, Cameron CE. Mechanisms of action of ribavirin against distinct viruses. Reviews in Medical Virology. 16: 37-48. PMID 16287208 DOI: 10.1002/Rmv.483  0.644
2005 Graci JD, Cameron CE. Lethal Mutagenesis: Exploiting Error-Prone Replication of Riboviruses for Antiviral Therapy Antiviral Drug Discovery For Emerging Diseases and Bioterrorism Threats. 203-220. DOI: 10.1002/0471716715.ch9  0.616
2004 Graci JD, Cameron CE. Challenges for the development of ribonucleoside analogues as inducers of error catastrophe. Antiviral Chemistry & Chemotherapy. 15: 1-13. PMID 15074710 DOI: 10.1177/095632020401500101  0.717
2002 Graci JD, Cameron CE. Quasispecies, error catastrophe, and the antiviral activity of ribavirin. Virology. 298: 175-80. PMID 12127780 DOI: 10.1006/Viro.2002.1487  0.7
2002 Harki DA, Graci JD, Korneeva VS, Ghosh SK, Hong Z, Cameron CE, Peterson BR. Synthesis and antiviral evaluation of a mutagenic and non-hydrogen bonding ribonucleoside analogue: 1-beta-D-Ribofuranosyl-3-nitropyrrole. Biochemistry. 41: 9026-33. PMID 12119016 DOI: 10.1021/Bi026120W  0.689
Show low-probability matches.